2026 Global: Ambulatory Cardiac Monitoring Market-Competitive Review (2032) report
Description
The 2026 Global: Ambulatory Cardiac Monitoring Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for ambulatory cardiac monitoring market by geography and historical trend. The scope of the report extends to sizing of the ambulatory cardiac monitoring market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The ambulatory cardiac monitoring market, valued at USD 7.55 billion in 2025 and projected to reach USD 11.74 billion by 2030, is dominated by ten major companies leveraging advanced ECG devices, mobile cardiac telemetry, and AI-driven diagnostics. Abbott Laboratories leads with its Assert-IQ insertable cardiac monitor, receiving CE Mark approval for long-term irregular heart rhythm detection, enhancing proactive care through continuous data streams. Medtronic plc holds a prominent position via comprehensive portfolios, including remote patient monitoring and acquisitions like PaceMate’s Paceart Optima for workflow optimization, supporting a 9.23% CAGR amid consolidation trends. Boston Scientific Corporation expands through deals like Bolt Medical’s assets in January 2025, integrating predictive analytics and therapy-diagnostics hybrids into platforms like BodyGuardian for wearable monitoring. GE HealthCare (formerly General Electric Company) excels in ECG and multi-parameter vital signs monitoring, bolstered by collaborations such as with AMC Health for RPM integration, securing third place in U.S. patient monitoring. Koninklijke Philips N.V. strengthened its offerings via the 2021 BioTelemetry acquisition, adding Holter, MCOT, and event recorders, while BioTel platforms now support seamless ambulatory diagnostics.
iRhythm Technologies Inc. disrupts with the Zio ECG patch, achieving 99% physician agreement on reports through FDA-cleared deep-learning algorithms for arrhythmia detection up to 14 days, shifting strategies toward at-home AI solutions. ZOLL Medical Corporation (Asahi Kasei Group) influences growth in MCT segments with a 13.2% CAGR, focusing on on-the-go devices for atrial fibrillation monitoring amid rising prevalence in aging populations. Biotronik SE & Co. KG advances with distributed products like InfoBionic’s MoMe Kardia since 2018, expanding cardiovascular portfolios for efficient remote care. NIHON KOHDEN CORPORATION and FUKUDA DENSHI contribute as key Asian players, with Nihon Kohden in arrhythmia devices and Fukuda in ECG systems, driving Asia Pacific’s 11.3% CAGR through partnerships and cyber-secure platforms. These firms prioritize AI firmware, battery life, and interoperability, with North America holding 42.8% share due to reimbursement and infrastructure advantages.
Emerging integrations like VitalConnect’s USD 100 million-funded VitalPatch and Biotricity’s device-neutral platform with B-Secur highlight competitive edges in multi-parameter wearables and data management. Leaders embed hospital system connectivity and cybersecurity, migrating from reactive ECG (37.64% share) to proactive telemetry, while IDTFs grow at 9.97% CAGR for scalable interpretations. Abbott, Medtronic, and Boston Scientific exhibit moderate concentration through acquisitions, outpacing innovators like Cardiac Insight’s Cardea SOLO for 7-day home ECG analytics. Market evolution favors patch-free sensors and RF sensing, elevating algorithm quality over pricing for sustained leadership amid 15.23% arrhythmia monitoring CAGR to 2032.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for ambulatory cardiac monitoring market by geography and historical trend. The scope of the report extends to sizing of the ambulatory cardiac monitoring market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The ambulatory cardiac monitoring market, valued at USD 7.55 billion in 2025 and projected to reach USD 11.74 billion by 2030, is dominated by ten major companies leveraging advanced ECG devices, mobile cardiac telemetry, and AI-driven diagnostics. Abbott Laboratories leads with its Assert-IQ insertable cardiac monitor, receiving CE Mark approval for long-term irregular heart rhythm detection, enhancing proactive care through continuous data streams. Medtronic plc holds a prominent position via comprehensive portfolios, including remote patient monitoring and acquisitions like PaceMate’s Paceart Optima for workflow optimization, supporting a 9.23% CAGR amid consolidation trends. Boston Scientific Corporation expands through deals like Bolt Medical’s assets in January 2025, integrating predictive analytics and therapy-diagnostics hybrids into platforms like BodyGuardian for wearable monitoring. GE HealthCare (formerly General Electric Company) excels in ECG and multi-parameter vital signs monitoring, bolstered by collaborations such as with AMC Health for RPM integration, securing third place in U.S. patient monitoring. Koninklijke Philips N.V. strengthened its offerings via the 2021 BioTelemetry acquisition, adding Holter, MCOT, and event recorders, while BioTel platforms now support seamless ambulatory diagnostics.
iRhythm Technologies Inc. disrupts with the Zio ECG patch, achieving 99% physician agreement on reports through FDA-cleared deep-learning algorithms for arrhythmia detection up to 14 days, shifting strategies toward at-home AI solutions. ZOLL Medical Corporation (Asahi Kasei Group) influences growth in MCT segments with a 13.2% CAGR, focusing on on-the-go devices for atrial fibrillation monitoring amid rising prevalence in aging populations. Biotronik SE & Co. KG advances with distributed products like InfoBionic’s MoMe Kardia since 2018, expanding cardiovascular portfolios for efficient remote care. NIHON KOHDEN CORPORATION and FUKUDA DENSHI contribute as key Asian players, with Nihon Kohden in arrhythmia devices and Fukuda in ECG systems, driving Asia Pacific’s 11.3% CAGR through partnerships and cyber-secure platforms. These firms prioritize AI firmware, battery life, and interoperability, with North America holding 42.8% share due to reimbursement and infrastructure advantages.
Emerging integrations like VitalConnect’s USD 100 million-funded VitalPatch and Biotricity’s device-neutral platform with B-Secur highlight competitive edges in multi-parameter wearables and data management. Leaders embed hospital system connectivity and cybersecurity, migrating from reactive ECG (37.64% share) to proactive telemetry, while IDTFs grow at 9.97% CAGR for scalable interpretations. Abbott, Medtronic, and Boston Scientific exhibit moderate concentration through acquisitions, outpacing innovators like Cardiac Insight’s Cardea SOLO for 7-day home ECG analytics. Market evolution favors patch-free sensors and RF sensing, elevating algorithm quality over pricing for sustained leadership amid 15.23% arrhythmia monitoring CAGR to 2032.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
